The FDA Just Made It Easier to Sell Nicotine Pouches. The Drug Meant to Help You Quit Got Turned Away.

Walk into most gas stations now and there’s a small, quiet display near the register that didn’t exist five years ago: tins of nicotine pouches, stacked next to the gum and mints, no smoke, no vapor, no smell. That display is the product of an FDA authorization pathway most of the people reaching for it have never heard of, and this week that pathway is about to get faster.

The FDA is putting real regulatory energy into making nicotine easier to buy. It has not put the same energy into making it easier to quit — and the gap between those two priorities is the whole story right now.

What’s Actually Changing at the FDA

According to reporting by the Wall Street Journal, relayed by Nicotine Insider, the FDA plans to revisit its 2021 rule governing the Premarket Tobacco Product Application, or PMTA — the scientific review every vape, pouch, or new tobacco product legally needs to pass before it can be sold in the U.S. The agency wants to simplify the study requirements companies must submit and speed up review timelines, moving away from what Center for Tobacco Products Director Bret Koplow called a “one-size-fits-all approach” that treated a nicotine pouch the same as a flavored disposable vape aimed at teenagers.

There’s a real access problem behind the push. Fewer than 100 reduced-risk nicotine products have full FDA marketing authorization, compared with thousands of authorized combustible cigarette products — meaning the legal market for people trying to switch away from smoking to something less harmful is a fraction of the size of the market for cigarettes themselves. Under a pilot program launched in 2025, the agency has already cut nicotine-pouch review times to under 180 days and trimmed its application backlog by roughly 70% since May. Haypp Group’s regulatory affairs VP, Laura Leigh Oyler, told the outlet the overhaul “isn’t just welcome, it’s necessary to bring the FDA in line with what Americans should expect from their government.”

Here’s the part that gets lost in industry framing, though: right now, every single one of the 43 FDA-authorized nicotine pouch products on the market comes from exactly two companies — Swedish Match, which makes ZYN, and Helix Innovations, which makes on!. A faster PMTA process means more competitors, yes. It also means more of the product category people who use nicotine tend to escalate toward, moving from patch-strength doses to pouches that deliver considerably more nicotine per unit, faster.

The Drug Meant to Help You Quit Is the One Still Waiting

While the FDA works to speed up the pipeline for new nicotine products, the pipeline for the medication built to help people stop using nicotine altogether just hit a wall. Cytisinicline — a plant-derived compound that would have been the first new smoking-cessation drug approved in the U.S. in nearly twenty years — was supposed to clear the FDA on June 20. Instead, Achieve Life Sciences received a Complete Response Letter, the FDA’s formal way of saying “not yet.” The letter, per the company’s own SEC filing, raised no concerns about the drug’s clinical effectiveness or safety. The holdup was manufacturing: outstanding inspection findings at a contract manufacturing facility, and product labeling that wasn’t finalized in time.

That’s an unglamorous, bureaucratic reason for a delay, but the consequence is not unglamorous at all: a medication that showed people were meaningfully more likely to quit smoking, and — in early trial data — more than twice as likely to quit vaping specifically, is now not expected on pharmacy shelves until sometime after it’s resubmitted in the fourth quarter of this year, with approval anticipated in the first half of 2027. Achieve has since moved manufacturing to a U.S.-based facility, Adare Pharma Solutions, to fix the problem. Whether that fixes the optics of an agency that can find 180 days to authorize a new nicotine pouch flavor but needed a full year and a resubmission cycle to clear a cessation drug’s paperwork is a separate question.

Achieve has since moved manufacturing to a U.S.-based facility, Adare Pharma Solutions, to fix the problem.

Why This Actually Matters If You’re in Recovery From Something Else

If you’re working a recovery program for opioids, alcohol, or a stimulant, and you also use nicotine — smoking, vaping, or pouches — you are the majority, not the exception. NIDA research finds that nearly half of all cigarettes sold in the U.S. — 44% — are smoked by people with a mental illness or a substance use disorder, a rate wildly out of proportion to their share of the population, and it’s not a coincidence. Nicotine dependence shares the same reward-pathway mechanics as the substance that brought you into treatment in the first place, and continuing to use it is associated with worse long-term recovery outcomes across the board — not because nicotine itself is as dangerous as fentanyl or alcohol, but because an active dependency, any active dependency, keeps that same neurological loop running.

What actually works, right now, hasn’t changed while the FDA sorts out its priorities. Nicotine replacement therapy — patches, gum, lozenges — is available over the counter today. Generic varenicline, the closest existing equivalent to what cytisinicline is trying to become, requires a prescription but is effective and inexpensive. Free quitline support (1-800-QUIT-NOW) pairs medication with the kind of behavioral coaching that meaningfully raises quit rates on its own. None of that is waiting on a PMTA overhaul or a 2027 approval date.

A Fight the Industry Has Had Before

This isn’t the first time regulators have had to referee a fight between what’s fast to sell and what’s proven to help people quit. In April 1994, the chief executives of the seven largest U.S. tobacco companies sat before Congress and testified, under oath, that they did not believe nicotine was addictive — a claim internal company documents would later prove they knew was false. That hearing became a turning point: it fed directly into the 1998 Master Settlement Agreement, and eventually into the 2009 law that gave the FDA any regulatory authority over tobacco products at all. The pattern since has been consistent. Industry moves fast, the evidence catches up slowly, and Congress or the courts end up forcing the correction. The PMTA overhaul and the cytisinicline delay are this decade’s version of the same imbalance — just with less lying under oath and more paperwork.

What to Reach For Tonight

None of this changes what’s sitting in a pharmacy near you right now. If nicotine is part of what you’re carrying alongside a bigger recovery, the patch or the gum or the quitline call doesn’t need FDA news to work — it already does, tonight, whether or not cytisinicline ever makes it to market. Read more on the /newsroom/category/science-medicine beat and ongoing /newsroom/substances/nicotine-tobacco coverage as the PMTA overhaul and the cessation-drug pipeline both play out this year.